Form 4: Enliven Therapeutics Chief Scientific Officer Sells Shares Under Pre-Arranged Trading Plan

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 12,500 shares of common stock for approximately $21.3966 per share, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), sold 12,500 shares of common stock.
• The transaction occurred on June 20, 2025.
• The shares were sold at a weighted average price of $21.3966 per share, with individual trades ranging from $21.1228 to $22.0249.
• Following the sale, Mr. Lyssikatos beneficially owns 965,188 shares of Enliven Therapeutics common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Lyssikatos on November 15, 2024.

Sentiment

Score: 6

Explanation: The sale of shares by a Chief Scientific Officer is generally viewed as a minor negative, but the fact that it was executed under a pre-arranged Rule 10b5-1 trading plan adopted months prior (November 15, 2024) significantly reduces any negative implications, suggesting a planned liquidity event rather than a reaction to new, adverse information.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on new, non-public information, which mitigates the negative signal often associated with insider sales.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the direct ownership stake of a key executive, which can sometimes be perceived as a slight reduction in alignment with shareholder interests.

Future Outlook

The document, a Form 4, does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details a routine insider stock transaction and does not provide information relevant to broader industry trends or competitive analysis within the biotechnology or pharmaceutical sector.

Related Party Transactions

• The shares are held indirectly by The Lyssikatos Revocable Trust 12/15/2011, for which the Reporting Person serves as trustee. This indicates a transaction involving a trust controlled by the insider, which is a common form of indirect beneficial ownership.

Stakeholder Impact

• Shareholders: The sale slightly reduces the direct ownership stake of a key executive, but the pre-planned nature of the sale under Rule 10b5-1 minimizes concerns about management's confidence in the company.
• Employees, Customers, Suppliers, Creditors: The transaction is unlikely to have any direct impact on these stakeholders.

Key Dates

Recommendation

Keywords

Enliven Therapeutics, ELVN, Joseph P. Lyssikatos, Chief Scientific Officer, Insider Sale, Form 4, SEC Filing, Stock Transaction, Rule 10b5-1 Plan, Equity Sales